Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

References

• Pewforum.org [homepage on the Internet]The future of the global Muslim population: projections for 2010–2030Washington, DCPew Research Center2011 Available from: http://www.pewforum.orgAccessed August 28, 2013
   Google Scholar
• Idf.org [homepage on the Internet]IDF Diabetes Atlas5th edBrussels, BelgiumInternational Diabetes Federation2011 Available from: http://www.idf.org/diabetesatlasAccessed August 28, 2013
   Google Scholar
• SaltiIBenardEDetournayBA population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) studyDiabetes Care200427102306231115451892
   PubMed Web of Science ®Google Scholar
• Al-AroujMAssaad-KhalilSBuseJRecommendations for management of diabetes during Ramadan: update 2010Diabetes Care20103381895190220668157
   PubMed Web of Science ®Google Scholar
• FatimaJKaroliRChandraANaqviNRamadan fasting in patients with type 2 diabetes mellitus: experience from a teaching hospitalIndian J Endocrinol Metab201216232332422470883
   PubMedGoogle Scholar
• AlmaatouqMAPharmacological approaches to the management of type 2 diabetes in fasting adults during RamadanDiabetes Metab Syndr Obes2012510911922654520
   PubMedGoogle Scholar
• RashedAHThe fast of RamadanBMJ199230468265215221559053
   PubMedGoogle Scholar
• AmielSADixonTMannRJamesonKHypoglycaemia in Type 2 diabetesDiabet Med200825324525418215172
   PubMed Web of Science ®Google Scholar
• AhmadJPathanMFJaleelMADiabetic emergencies including hypoglycemia during RamadanIndian J Endocrinol Metab201216451251522837906
   PubMedGoogle Scholar
• LokeSCRahimKFKanesvaranRWongTWA prospective cohort study on the effect of various risk factors on hypoglycaemia in diabetics who fast during RamadanMed J Malaysia20106513621265238
   PubMedGoogle Scholar
• AhrénBAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesVasc Health Risk Manag2013915516323637538
   PubMedGoogle Scholar
• SchernthanerGGrimaldiADi MarioUGUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patientsEur J Clin Invest200434853554215305887
   PubMed Web of Science ®Google Scholar
• TayekJSUR receptor activity vs incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabeticsDiabetes Obes Metab200810111128112918671799
   PubMed Web of Science ®Google Scholar
• AravindSRAl TayebKIsmailSBHypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational studyCurr Med Res Opin20112761237124221506631
   PubMed Web of Science ®Google Scholar
• DavidsonMBRecommendations for management of diabetes during RamadanDiabetes Care200629374516526119
   PubMed Web of Science ®Google Scholar
• ElhaddTAAl-AmoudiAARecommendations for management of diabetes during RamadanDiabetes Care200629374474516526118
   PubMed Web of Science ®Google Scholar
• HuiEDevendraDDiabetes and fasting during RamadanDiabetes Metab Res Rev201026860661020939000
   PubMed Web of Science ®Google Scholar
• AzizKMEffect of fasting ramadan in diabetes control status – application of extensive diabetes education, serum creatinine with HbA1c statistical ANOVA and regression models to prevent hypoglycemiaRecent Pat Endocr Metab Immune Drug Discov20137323325123964680
   PubMedGoogle Scholar
• AhrénBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes Obes Metab201113977578321507182
   PubMed Web of Science ®Google Scholar
• DejagerSSchweizerAMinimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes managementDiabetes Ther201122516622127800
   PubMedGoogle Scholar
• Al SifriSBasiounnyAEchtayAThe incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trialInt J Clin Pract20116511132114021951832
   PubMedGoogle Scholar
• AravindSRIsmailSBBalamuruganRHypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic studyCurr Med Res Opin20122881289129622738801
   PubMed Web of Science ®Google Scholar
• DevendraDGohelBBravisVVildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during RamadanInt J Clin Pract200963101446145019678856
   PubMed Web of Science ®Google Scholar
• HassaneinMHanifWMalikWComparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR studyCurr Med Res Opin20112771367137421568833
   PubMed Web of Science ®Google Scholar
• HanifWMalikWHassaneinMTreatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during RamadanCurr Med Res Opin201329780781123659561
   PubMed Web of Science ®Google Scholar
• SheteAVVIndian Ramadan study groupReal life experience of usage of vildagliptin versus sulfonylurea therapy in fasting patients with type 2 diabetes during Ramadan: an Indian experienceDiabetologia201154Suppl 1S342S343
   Google Scholar
• FoleyJESreenanSEfficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetesHorm Metab Res2009411290590919705345
   PubMed Web of Science ®Google Scholar
• HalimiSLevyMHuetDQuereSDejagerSExperience with vildagliptin in type 2 diabetic patients fasting during ramadan in France: insights from the VERDI studyDiabetes Ther Epub8312013
   PubMed Web of Science ®Google Scholar
• Al-AroujMHassounAAMedlejRThe effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE studyInt J Clin Pract2013671095796324001317
   PubMed Web of Science ®Google Scholar
• IsraelianZSzokeEWoerleJMultiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitusMetabolism200655559359816631434
   PubMed Web of Science ®Google Scholar
• AhrénBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab20099441236124319174497
   PubMed Web of Science ®Google Scholar
• FarngrenJPerssonMSchweizerAFoleyJEAhrenBVildagliptin reduces glucagon during hyperglycemia and sustains glucagon counter-regulation during hypoglycemia in type 1 diabetesJ Clin Endocrinol Metab201297103799380622855332
   PubMed Web of Science ®Google Scholar
• AhrénBFarngrenJPerssonMSchweizerAFoleyJImproved glucagon dynamics during hypoglycemia and food-rechallenge by DPP-4 inhibition by vildagliptin in insulin-treated patients with type 2 diabetesDiabetologia201356Suppl 1S51
   Google Scholar
• ChristensenMVedtofteLHolstJJVilsbollTKnopFKGlucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humansDiabetes201160123103310921984584
   PubMed Web of Science ®Google Scholar
• DavisJASinghSSethiSNature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animalsIndian J Pharmacol201042422923320927248
   PubMed Web of Science ®Google Scholar
• Landstedt-HallinLAdamsonULinsPEOral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab19998493140314510487677
   PubMed Web of Science ®Google Scholar
• PeaceySRRostami-HodjeganAGeorgeETuckerGTHellerSRThe use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humansJ Clin Endocrinol Metab1997825145814619141533
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEFerranniniEChanges in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapyDiabetes Care201033473073220067974
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc201260461663122376048
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsVildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST) Available from: http://clinicaltrials.gov/show/NCT01758380. NLM identifier: NCT01758380Accessed November 25, 2013
   Google Scholar